and , and IRONOUT HF200 ; these are summarised in Table 51 below. Four trials compared IV iron with placebo; of which 1 trial also included an oral iron arm. A further single study compared oral iron with placebo. Two of the trials were in patients with anaemia; the other 3 trials included both anaemic and non-anaemic patients. Evidence from these studies is summarised in the clinical evidence summaries below (Table 52 toTable 54). See also the study selection flow chart in Appendix C, forest plots in Appendix E, study evidence tables in Appendix F, GRADE tables in Appendix H and excluded studies list in Appendix I. Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Table 51: Summary of studies included in the review Study Intervention and comparison Population Outcomes Comments CONFIRM- HF trial: Ponikowski Intervention: Two injections (at baseline and week 6) of IV iron (ferric carboxymaltose) each equivalent to 500 or 1000 mg of iron, depending on weight and Hb. Maintenance injections of 500 mg iron at weeks 12, 24 and 36 if ID still present. Control: Matching placebo (saline solution) N = 304 Stable ambulatory HF patients with ID NYHA class II or III LVEF 45% Elevated NPs Hb <15 g/dL at screening visit Study duration: Mortality Quality of life KCCQ) Hospitalisation Exercise tolerance Discontinuation due to adverse events Drug related vascular disorders Drug related gastrointestinal disorders FAIR-HF trial: Anker (Anker , Comin-colet , Filippatos , Gutzwiller , Ponikowski ) Intervention: Weekly injections of IV iron (ferric carboxymaltose) equivalent to 200 mg iron, until week 8 or week 12, depending on required iron-repletion dose. Maintenance injections every four weeks until week 24. 